| 順位 |
タイトル |
掲載号 |
著者 |
| 1 |
The Japan Glaucoma Society guidelines for glaucoma 5th edition |
67.2 |
Yoshiaki Kiuchi, Toshihiro Inoue, Nobuyuki Shoji, Makoto Nakamura, Masaki Tanito & Glaucoma Guideline Preparation Committee, Japan Glaucoma Society |
| 2 |
Meibomian Gland Dysfunction Clinical Practice Guidelines |
67.4 |
Shiro Amano, Jun Shimazaki, Norihiko Yokoi, Yuichi Hori, Reiko Arita & Committee for Meibomian Gland Dysfunction Clinical Practice Guidelines |
| 3 |
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial |
67.3 |
Masahiko Shimura, Shigehiko Kitano, Nahoko Ogata, Yoshinori Mitamura, Hideyasu Oh, Haruka Ochi, Shino Ohsawa, Akito Hirakata & YOSEMITE and RHINE Investigators |
| 4 |
Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease |
68.3 |
Takahiro Koizumi, Takahiro Tanaka, Kazuki Umeda, Daisuke Komiyama & Hiroto Obata & TENAYA and LUCERNE Investigators |
| 5 |
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial |
67.3 |
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle Ayame Okada & TENAYA and LUCERNE Investigators |